Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Trial Patented Indication Carve Out | Mintz - Intellectual Property Viewpoints

In a precedential opinion issued on April 11, 2024 in Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc., Nos. 22-2153, 23-1952, the U.S. Court of Appeals for the Federal...

Related Keywords

Delaware ,United States ,Richardg Andrews , ,Alvogen Inc ,Salix Pharmaceuticals Ltd ,Alkemlaboratories Ltd ,Norwich Pharmaceuticals Inc ,Us Court ,Us District Court ,Salix Pharmaceuticals ,Pharmaceuticals Inc ,Federal Circuit ,Laboratories Ltd ,Defendant Norwich ,Abbreviated New Drug Application ,Orange Book ,Judge Richard ,Judge Andrews ,Federal Rule ,Civil Procedure ,Polymorph Patents Affirmed Invalid ,Motion Denial Affirmed ,